Joincare Pharmaceutical Group Industry Co.Ltd(600380) ( Joincare Pharmaceutical Group Industry Co.Ltd(600380) ) announced on April 24 that the company achieved an operating revenue of 4.657 billion yuan in the first quarter of 2022, a year-on-year increase of 12.36%; The net profit attributable to the shareholders of the listed company was 461 million yuan, a year-on-year increase of 25.52%; The basic earnings per share was 0.24 yuan, a year-on-year increase of 28.49%.
The company said that the sales of main varieties in the company’s key specialty areas achieved stable growth, driving the year-on-year growth of operating revenue. According to the data, during the reporting period, the operating revenue of chemical agents was 2.737 billion yuan, a year-on-year increase of 24.54%, of which the revenue of respiratory products was 363 million yuan, a year-on-year increase of 324.90%; The revenue of anti infection products was 350 million yuan, a year-on-year increase of 26.91%; The revenue of gastrointestinal products was 1.07 billion yuan, a year-on-year increase of 5.90%; The revenue of sex hormone products was 737 million yuan, a year-on-year increase of 22.84%. The revenue of APIs and intermediates was 1.406 billion yuan, a year-on-year increase of 14.90%.
